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Introduction
Drugs with antihistamine action are among the commonly 
prescribed medicines in pediatrics for the symptomatic treatment of 
various allergic disorders such as, seasonal and perennial allergic rhinitis, 
conjunctivitis, atopic dermatitis or chronic urticaria. Antihistamines 
presently available on the market have been classified as first, second 
or third generation drugs and they differ in the chemical structures, 
pharmacodynamics, pharmacokinetics and adverse health events [1-5]. 
First-generation antihistamines used traditionally (diphenhydramine, 
chlorpheniiramine, clemastine, hydroxyzine, triprolidine and 
promethazine) are highly lipid soluble, have a low molecular weight 
and a high affinity for cerebral H1 receptors. They easily cross the blood 
brain barrier and show highly sedating effect on central nervous system 
even at low therapeutic doses. Sedation reflects the impairment of 
cognitive functions such as attention, memory, language, coordination 
or psychomotor performance, which can hinder daily activities, where 
mental concentration and skill are required [6-11]. As children are more 
sensitive to the side-effects of drugs than adults, the side effects may 
have implications for their further long-term intellectual development.
The newer generation antihistamines (astemizole, terfenamide, 
loratanide, cetirizine, fexofenadine) known as “nonsedative 
antihistamines”, like the first-generation antihistamines have a similar 
affinity for the H1 receptor. However, having greater molecular 
weight they do not easily cross the blood brain barrier and do not 
cause unwanted CNS side effects. Hence, most newer-generation 
antihistamines have a much more favourable therapeutic index [12-16]. 
Most of the studies to assess the sedative effect of the H1 antagonists 
were carried out in the groups of asthmatic children. Although asthma 
is not a disease that directly affects cognitive development, but the 
effect of the disease may delay a child’s cognitive development since 
children in severe asthma attacks may not receive adequate care in an 
optimal way and experience anoxic episodes. Subsequently, a child 
experiencing many anoxic insults may suffer from a cognitive delay due 
to the insufficient supply of oxygen to the brain [17].
The main purpose of this prospective epidemiologic population 
based study was to establish whether an early use of the first-generation 
antihistamines by young non-asthmatic children could have affected 
their cognitive function measured at the age of 7. The size of the effect 
on the cognitive scores was measured by the Wechsler Intelligence Scale 
for Children (WISC-R) and adjusted for major confounders known to 
be important for children cognitive development such as, maternal 
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Abstract
As the allergic diseases increase steadily worldwide, the main goal of the study was to assess the association 
between the early intake of the first-generation sedative antihistamines in young non-asthmatic children and their 
cognitive function at the age of 7. The size of the exposure effect was measured by the Wechsler intelligence Scale 
for Children (WISC-R) and adjusted in multivariable models for major confounders known to be important for children 
cognitive development. The study included 212 children who were non-asthmatic and completed the monitoring of 
antihistamines intake over 3 years preceding the WISC-R intelligence testing. 
While the first-generation drugs were used by 36.7% children and the newer generation by 39.6%, both 
categories of drugs were taken by 17.8% children. The analysis showed the deficit of 12 points on the verbal WISC-R 
IQ scale only in children who used the first- generation antihistamines for a longer time (beta coeff.=-11.7, 95% CI: 
-19.6, -3.7) compared to non-users. Out of the covariates included in the multivariable regression models, maternal
education (beta coeff.=0.92, 95% CI: 0.37, 1.46) and breastfeeding at least for 6 months (beta coeff.=3.29; 95% CI:
0.34, 6.23) showed a significant positive impact on the verbal IQ. Intake of the newer generation antihistamines were
associated neither with verbal nor performance IQ scores.
Concluding, the results suggest that the “sedative antihistamines” have a negative impact on the verbal but not 
performance IQs of young children if drugs were used over a longer period. The weaker verbal communication ability 
of young children may hinder the cognitive development of children and be associated with relatively poor school 
academic achievements.
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education, the child’s gender, breastfeeding practice, the presence of 
older siblings, and environmental tobacco smoke (ETS).  
Material and Methods 
This is part of an ongoing comparative longitudinal investigation on 
the health impact of prenatal exposure to outdoor/indoor air pollution 
in infants and children being conducted in Krakow, Poland. As 
described previously [18], between January 2001 and February 2004, we 
recruited a total of 484 womens between 8 and 13 weeks pregnant, who 
had born term babies (>36 weeks of gestation) and were registered at 
prenatal healthcare clinics in the central area of Krakow, where they had 
also lived for at least a year before screening. Pregnant women visiting 
the prenatal clinic received a letter of introduction and answered a short 
screening questionnaire to determine whether they met the eligibility 
criteria-age ≥ 18 years, non-smoking, singleton pregnancy, no current 
occupational exposure to known developmental toxicants and no 
history of illicit drug use, pregnancy-related diabetes, or hypertension. 
All participants received verbal and written information about the 
study. Ethical permission for the study was granted by the Bio-ethical 
Committee of Jagiellonian University Medical College. 
The present study included 212 term babies who were non-
asthmatic and completed the monitoring of intake of antihistamine 
drugs over 3 years preceding the WISC-R intelligence testing at the 
age 7. Estimated daily intake of oral antihistamines by children over 
the 3-years period preceding WISC-R testing were based on regular 
face-to-face interviews performed every 6 months by the trained field 
workers with mothers. Name(s) of the drug(s) reported by mothers 
had to be supported by showing the interviewer original packagings 
or containers of the drug(s) used. Detailed data on maternal education 
was used as a proxy for social class, intellectual ability and quality of 
parenting. Mothers were also asked whether the infant had ever been 
breastfed, and, if so, the age of the baby (in months) when exclusive 
breastfeeding was stopped. Exclusive breastfeeding was assumed if the 
child received only breast milk, and no other liquids or solids with the 
exception of medicine, or mineral supplements. Mixed feeding was 
assumed when the child received both breast milk and formula or only 
formula since birth. As maternal intelligence is a known correlate of 
child cognitive development, we administered the Test of Nonverbal 
Intelligence (TONI-3) to the mothers at the 4th year of follow-up. Data 
on the presence of tobacco smoking household members was used to 
define environmental tobacco smoke (ETS) at home.
Mental development testing of children
At age 7, the WISC-R was used, which is the most widely used 
intelligence and neuropsychological assessment and is considered to be 
a valid and reliable measure of general intelligence in children [19,20]. 
It has also been found to be a good measure of both inductive and 
deductive reasoning but it also measures knowledge and skills primarily 
influenced by biological and socio-cultural factors. The WISC-R 
includes questions of general knowledge, traditional arithmetic 
problems, vocabulary, completion of mazes, and arrangements of 
blocks and pictures and yields three IQ (intelligence quotient) scores, 
based on an average of 100, as well as subtests and index scores. WISC-R 
subtests measure specific verbal and performance abilities. The child's 
verbal IQ score (VIQ) is derived from scores on six of the subtests: 
information, digit span, vocabulary, arithmetic, comprehension, and 
similarities. The information subtest is a test of general knowledge, 
including questions about geography and literature. The digit span 
subtest requires the child to repeat strings of digits recited by the 
examiner. The vocabulary and arithmetic subtests are general measures 
of the child's vocabulary and arithmetic skills. The comprehension 
subtest asks the child to solve practical problems and explain the 
meaning of simple proverbs. The similarities subtest asks the child to 
describe the similarities between pairs of items, for example that apples 
and oranges are both fruits. The child's performance IQ score (PIQ), 
which is a measure of non-verbal intellectual abilities is derived from 
scores on the seven subtests: picture completion, picture arrangement, 
block design, object assembly, coding, mazes, and symbol search. In the 
picture completion subtest, the child is asked to complete pictures with 
missing elements. The picture arrangement subtest entails arranging 
pictures in order to tell a story. The block design subtest requires the 
child to use blocks to make specific designs. The object assembly subtest 
asks the child to put together pieces in such a way as to construct an 
entire object. In the coding subtest, the child makes pairs from a series 
of shapes or numbers. The mazes subtest asks the child to solve maze 
puzzles of increasing difficulty. The symbol search subtest requires the 
child to match symbols that appear in different groups. Scores on the 
performance subtests are based on both the speed of response and the 
number of correct answers. The Wechsler scales were standardized 
for Polish children and are meant to be representative of the Polish 
population. The practical standardization of these tests was done 
during team practice sessions with Ms. Maria Butscher, a psychologist 
from the Jagiellonian University Medical College, who subsequently 
evaluated the IQ scoring.
Statistical data analysis
 In the descriptive analysis, the distribution of various parameters 
related to the women and newborns under study were presented. Chi-
square statistics (nominal variables) and analysis of variance (numerical 
variables) tested differences between subgroups included in the study 
and that who did not fully participate in the monitoring of the drug 
intake. The relationship between IQ scores of children and the exposure 
to antihistamines was evaluated by linear multivariable regression 
models. The models computed regression coefficients of the dependent 
variable (intelligence IQ scores) on the main predictor variable 
(antihistamines) accounting for potential confounders or modifiers 
(gender of child, maternal education, parity, breastfeeding practice 
and ETS). As the correlation coefficients between cognitive scores 
achieved by children and maternal education (number of schooling 
years) and maternal IQ assessed by TONI test did not differ, we have 
chosen to consider only maternal education as a proxy for maternal 
intellectual ability and quality of parental care. All statistical analyses 
were performed with STATA 12.1 version software for Windows.
Results
General characteristics of the study were presented in Table 1. 
As the characteristics of the subjects included in the analysis did not 
reveal significant differences compared with the group of children 
who dropped out of the study, except for the children’s gender, we may 
assume that the material included in the analysis was representative of 
the population sample recruited initially (Table 2).
Overall mean VIQ scores in the study population was a little 
lower (mean=119.8; 95% CI: 118.4-121.3) than that for PIQ scores 
(mean=124.6; 95% CI: 122.9-126.3), but the difference was statistically 
insignificant. Out of the whole study sample, 56% children took 
antihistamines of various generations over shorter or longer period. 
The first-generation drugs were used by 36.7% children and the newer 
generation drugs by 39.6% children; both categories of drugs were 
taken by 17.8% children. The average use of the first generation drugs 
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was 9 days (95% CI: 8.9-9.7 days), and the newer generation drugs were 
used much longer i.e., 48 or more days (95% CI: 46.8-48.6). 
While there was a significant negative trend of the verbal IQ scores 
with the use of the first-generation antihistamines, no such pattern was 
noticed in children who used the second or third generation drugs 
(Table 3). The distribution of verbal IQ scores was markedly shifted 
to lower values in the group of children who were longer exposed to 
antihistamines of the first- generation (Figure 1). 
In order to assess the adjusted impact of the first-generation 
antihistamines on IQ WISC-R scales, multivariable linear regression 
models were used, where a set of potential confounding variables 
(maternal education, gender of child, parity, breastfeeding practice, 
ETS, and co-exposure to the newer generation drugs) were included 
(Tables 4-6). The significant deficit of 12 points on the verbal IQ scale 
attributable to the first- generation antihistamines was noticed if used 
longer (beta coeff.=-11.7, 95% CI: -19.6, -3.7) (Table 4). Out of the 
confounders inserted in the regression models, maternal education 
(beta coeff.=0.92, 95% CI: 0.37, 1.46) and breastfeeding for 6 months 
or longer (beta coeff.=3.29; 95% CI: 0.34, 6.23) showed a significant 
positive impact on cognitive function. 
Table 5 and 6 show that the negative effects of the first-generation 
antihistamines on the performance and full Wechsler IQ scales were 
insignificant and the beneficial impact of education and breastfeeding 
Variables Total
N=225 
Use of antihistamine 
drugs
P for 
difference
 (-) N=147 (+) N=78
Maternal age: mean 27.83 28.24 27.06 0.0157
SD 3.481 3.415 3.495
Maternal education:
(years of schooling)
mean 15.80 15.90 15.62 0.4580
SD         2.711 2.754 2.635
Parity:    1
≥ 2
n (%) 146 (64.9) 91 (61.9) 55 (70.5) 0.2540
n (%)   79 (35.1) 56 (38.1) 23 (29.5)
Gender:  Boys
Girls
n (%)     104 (46.2) 64 (43.5) 40 (51.3) 0.3328
n (%) 121 (53.8) 83 (56.5) 38 (48.7)
Gestational age:
(weeks) >36
mean 39.44 39.49 39.36 0.3975
SD 1.101 1.043 1.206
Birth weight (g): mean 3424.7 3438.8 3398.1 0.5033
SD 432.89 438.67 423.29
Length at birth (cm): mean 54.82 54.93 54.60 0.3690
SD 2.611 2.691 2.457
Head circumference 
(cm):
mean 33.90 33.94 33.83 0.5972
SD 1.420 1.406 1.454
Breastfeeding 
exclusive >6 months   
n (%) 62 (27.6) 45 (30.6) 17 (21.8) 0.2106
Postnatal ETS 
(1-7 age)
n (%) 32 (14.4) 22 (15.2) 10 (13.0) 0.8099
Missing 
date
3 2 1
Table 1: Characteristics of the study sample and the intake of the first-generation 
antihistamines by non asthmatic children.
Variables Total
N= 484
 Monitoring 
N=225
Monitoring 
was not 
completed 
N=259
P for 
difference
Maternal age: mean 27.55 27.83 27.31 0.1069
SD 3.580 3.481 3.653
Maternal education:
(years of schooling)
mean 15.56 15.80 15.36 0.0795
SD         2.759 2.711 2.790
Parity:    1
≥ 2
n (%) 307 (63.4) 146 (64.9) 161 (62.2) 0.5985
n (%) 177 (36.6)   79 (35.1)   98 (37.8)
Gender:  Boys
Girls
n (%)    248 (51.2) 104 (46.2) 144 (55.6) 0.0492
n (%) 236 (48.8) 121 (53.8) 115 (44.4)
Gestational age:
 (weeks)>36
mean 39.54 39.44 39.62 0.0955
SD 1.141 1.101 1.170
Birth weight (g): mean 3443.0 3424.7 3459.0 0.3880
SD 435.90 432.89 438.71
Length at birth (cm): mean 54.75 54.82 54.69 0.5956
SD 2.615 2.611 2.622
Head circumference 
(cm):
mean 33.91 33.90 33.91 0.9437
SD 1.391 1.420 1.368
Breastfeeding 
exclusive >6 months  
n (%) 133 (27.5) 62 (27.6) 71 (27.4) 1.0000
Table 2: Characteristics of the children who completed the drug monitoring and 
those who failed to complete it.
IQ scores Intake of the first generation drugs* Nonparame-
tric test for 
trend
No-users 
exposure
N=173
Short 
intake
N=35
Moderate 
intake
N=9 
Long 
intake
N=7
IQ verbal 
scale
120.6
119.0-122.1
120.9
116.8-124.9
118.1
111.2-125.0
110.9
104.2-117.5
Z=-2.21
P=0.027
IQ non-
verbal scale
124.2
122.3-126.2
125.7
121.4-130.0
124.8
114.4-135.1
125.9
110.7-140.9
Z=0.62
0.538
IQ full 
scale
124.7
123.1-126.4
125.7
121.8-129.6
123.4
114.7-132.2
122.6
113.3-131.9
Z=-0.85
P=0.393
IQ scores Intake of the second and/or third generation 
drugs**
Nonparame-
tric test for 
trendNo-users 
exposure
N=136
Short 
intake 
 N=44
Moderate 
intake  
N=32
Long 
intake
N=13
IQ verbal 
scale
120.7
118.9-122.5
118.1
114.2-122.0
119.7
118.1-123,3
116.2
105.6-126.8
Z=-0.51
P=0.611
IQ non-
verbal scale
124.5
122.4-126.6
124.2
120.0-128.3
125.6
121.1-130.1
126.0
116.0-136.0
Z=0.23
P=0.818
IQ full scale 124.9
123.1-126.6
123.2
119.3-127.0
125.0
121.9-128.1
125.4
117.4-133.3
Z=0.21
P=0.832
Intake of the first generation drugs*
Short-term intake: 8-28 days (mean 15 days)
Moderate-term intake: 28-42 days (mean 35 days)
Long-term intake: 43-140 (mean 74 days)
Intake of the second and/or third  generation drugs**
Short-term intake: <189  days (mean 53 days)
Moderate-term intake: 190-364 days (mean 285 days)
Long-term intake: >364 days (mean 728 days) 
Table 3: Trends for cognitive function of children at age 7 and the intake of the 
antihistamine drugs over three years preceding IQ testing.
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Figure 1: Distribution patterns of WISC-R scores and the intake of the first 
generation antihistamines (dash line: mean score in non-users).
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were not seen (Table 4). As for the full IQ scale (Table 6) the positive 
effect of maternal education remained significant (beta coeff. 0.69; 95% 
CI: 0.13, 1.26). 
Figure 2 visualizes the patterns of relationship between the intake 
of the first and newer generation antihistamines and verbal IQ scores 
based on adjusted values estimated from multivariable regression 
models. While the exposure to the newer antihistamines did not affect 
verbal IQ scores, its level markedly decreased when the intake of the 
first-generation drugs was reported over longer time (more than 60 
days).
Discussion
Up to now the side-effects of the first-generation antihistamines 
on cognitive function of children have not been adequately studied. In 
contrast, the second-generation antihistamines have been subjected to 
many studies, which have provided a much better knowledge of their 
safety and optimal paediatric dosage in various allergic disorders. To 
our knowledge, this is the first pharmacoepidemiologic population 
based study performed in early childhood aimed at assessing the 
relationship between the intake of the first generation antihistamines 
and WISC-R test, which is the most widely used to measure intelligence 
of children and is considered to be a valid and reliable measure of general 
intelligence. The study revealed that the users of the first-generation 
Predictors Coef. T P>t [95% Conf. Interval]
Gender of child (girls) -1.73 -1.25 0.213 -4.48 1.06
Maternal education 0.92 3.34 0.001 .376 1.46
Parity (numer of older 
siblings)
-1.99 -1.78 0.077 -4.19 0.22
Exclusive breastfeeding 3.29 2.20 0.029 0.34 6.23
Postnatal exposure to 
ETS
-2.39 -1.09 0.277 -6.73 1.94
Intake of antihistamines (1st generation)
1. Short intake 1.242 0.64 0.525 -2.60 5.08
2. Moderate intake -4.25 -1.21 0.227 -11.16 2.67
3. Long intake -11.65 -2.89 0.004 -19.60 -3.69
Intake of antihistamines (2nd or 3rd generation)
1. Short intake -0.65 -0.35 0.723 -4.27 2.97
2. Moderate intake -0.73 -0.35 0.724 -4.78 3.33
3. Long intake 0.17 0.05 0.957 -5.97 6.30
Intake of the first generation drugs*
Short-term intake: 8-28 days (mean 15 days)
Moderate-term intake: 28-42 days (mean 35 days)
Long-term intake: 43-140 (mean 74 days)
Intake of the second and/or third  generation drugs**
Short-term intake: <189  days (mean 53 days)
Moderate-term intake: 190-364 days (mean 285 days)
Long-term intake: >364 days (mean 728 days) 
Table 4: Association between the verbal IQ scores and the intake of the first 
generation anti-histamines adjusted for potential confounders. Multivariable linear 
regression model.
Predictors Coef. T P>t [95% Conf. Interval]
Gender of child (girls) 2.71 1.51 0.132 -0.83 6.24
Maternal education 0.31 0.88 0.381 -0.39 1.01
Parity (numer of older 
siblings)
1.97 1.37 0.173 -0.87 4.81
Exclusive breastfeeding 1.59 0.83 0.410 -2.21 5.39
Postnatal exposure to 
ETS
-2.87 -1.01 0.312 -8.46 2.72
Intake of antihistamines (1st generation)
1. Short intake 2.20 0.88 0.382 -2.75 7.16
2. Moderate intake -0.17 -0.04 0.970 -9.09 8.74
3. Long intake 1.63 0.31 0.755 -8.63 11.89
Intake of antihistamines (2nd or 3rd generation)
1. Short intake 0.09 0.04 0.970 -4.57 4.75
2. Moderate intake 1.02 0.39 0.700 -4.20 6.25
3. Long intake -1.48 -0.37 0.713 -9.39 6.43
Intake of the first generation drugs*
Short-term intake: 8-28 days (mean 15 days)
Moderate-term intake: 28-42 days (mean 35 days)
Long-term intake: 43-140 (mean 74 days)
Intake of the second and/or third  generation drugs**
Short-term intake: <189  days (mean 53 days)
Moderate-term intake: 190-364 days (mean 285 days)
Long-term intake: >364 days (mean 728 days)
Table 5: Association between the performance IQ scores and the intake of the first 
generation anti-histamines adjusted for potential confounders. Multivariable linear 
regression model.
Predictors Coef. T P>t [95% Conf. Interval]
Gender of child (girls) 0.43 0.30 0.767 -2.44 3.30
Maternal education 0.69 2.41 0.017 0.13 1.26
Parity (numer of older 
siblings)
-0.12 -0.10 0.921 -2.42 2.19
Exclusive breastfeeding 2.66 1.70 0.090 -.418 5.74
Postnatal exposure to 
ETS
-2.91 -1.26 0.207 -7.44 1.62
Intake of antihistamines (1st generation)
1. Short intake 1.93 0.95 0.345 -2.09 5.95
2. Moderate intake -2.59 -0.70 0.482 -9.82 4.65
3. Long intake -5.98 -1.42 0.158 -14.30 2.34
Intake of antihistamines (2nd or 3rd generation)
1. Short intake -0.41 -0.21 0.832 -4.19 3.38
2. Moderate intake 0.26 0.12 0.903 -3.98 4.50
3. Long intake -0.64 -0.20 0.844 -7.01 5.78
Intake of the first generation drugs*
Short-term intake: 8-8 days (mean 15 days)
Moderate-term intake: 28-42 days (mean 35 days)
Long-term intake: 43-140 (mean 74 days)
Intake of the second and/or third  generation drugs**
Short-term intake: <189  days (mean 53 days)
Moderate-term intake: 190-364 days (mean 285 days)
Long-term intake: >364 days (mean 728 days)
Table 6: Association between the full IQ scores and the intake of the first generation 
anti-histamines adjusted for potential confounders. Multivariable linear regression 
model.
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Figure 2: Predicted VIQ scores by the number of days the antihistamines were 
used over 3-years period.
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antihistamines had achieved a significantly lower scoring on the verbal 
IQ scale (beta coeff.=-11.7, 95% CI: -19.6, -3.7) compared to non-users. 
All though the association between the first-generation antihistamines 
and the cognitive function of children was slightly attenuated in the 
multivariable regression model after accounting for major confounders, 
but the main effect remained stable and highly significant. Interestingly, 
the use of the first-generation drugs did not hinder the performance 
IQ scores. 
The findings of the study are of interest as they may explain the 
communication problems of children and their worse potentials 
for academic achievements at school. Newer non-sedating second-
generation H1-antihistamines appeared to be free from the unwanted 
side-effects and detrimental effects on mental functions. In this sense, 
our results strongly support earlier clinical observations suggesting an 
impairment of learning abilities of children under treatment of the first-
generation antihistamine drug [6,7,9-12]. 
At present, there is no definitive and clear explanation for the 
positive association between maternal education and neurocognitive 
development of children, which has been shown in our study. 
Educational level of mothers is not only a good proxy for maternal 
cognitive capacity and socio-economic status of the family, but it may 
be an indicator of other relevant factors such as maternal behavior, 
life style, dietary habits before and during pregnancy, all of which are 
important for the study of children’s health. With the exception of 
breastfeeding, none of the above-mentioned variables were considered 
in our analysis. Less educated mothers are possibly not as responsive 
to their infants’ needs as better educated mothers or they may present 
some less favorable behavior during early childhood. Children living in 
a poor socio-economic environment are more likely to be exposed to 
environmental hazards and the adverse effects may be more pronounced 
in lower compared to higher socio-economic groups. 
Moreover, studies carried out by Bellinger [21] suggest that social 
context also modifies the effects of chemical neurotoxins. For example, 
material hardship has been demonstrated to modify the neurotoxic 
effects of tobacco smoke in children in the study done by Rauh et al. 
[22]. The way in which maternal behavior may affect the development 
of children was discussed in a recently published paper by Surkan et 
al. [23].
Our study confirmed a positive effect of longer exclusive 
breastfeeding on the verbal IQ score, which by many authors is 
explained by the fact that breastfed and milk-formula-fed infants could 
have been influenced by omega-3 polyunsaturated fatty acids that are 
normally present in breast milk or other bioactive components essential 
for development [24,25]. However, there are other possible mechanisms 
that may explain the association between breastfeeding and child 
cognitive function since breastfeeding may be an indicator of a safe 
and sound maternal attachment status, which has been shown to have 
a positive influence on the child’s psychological development into later 
age [26-29]. Breastfeeding may also be a marker of other unmeasured 
maternal characteristics such as maternal intelligence. In our analysis, 
we did not consider maternal intelligence as it was found that maternal 
education correlated significantly with maternal cognitive capacity.
Weakness of the study results from the small size of the study sample 
and the lack of precise information on pediatric antihistamines doses 
used in early childhood. Moreover, we could not perform verification 
of maternal reports with medical records. However, strength of our 
study is the prospective design, and assessment of individual intake of 
antihistamine drugs by interviews with mothers at regular 6-months 
intervals preceding the health outcome measurement and controlling 
for several major confounding covariates. In addition, a set of 
relevant confounders of the relationship between the intake of drugs 
and cognitive development such as diagnosed asthma in children, 
chronic diseases of mothers or maternal active tobacco smoking, have 
been removed through entry criteria to the study. It is important to 
mention as well, that the assessment of the cognitive development of 
children was carried out by the trained staff using the Polish version 
of the Wechsler-R intelligence, adapted and standardized by the Polish 
Psychological Society. 
Conclusions
The first-generation antihistamines negatively affect verbal but not 
performance IQs of young children when they are used over a relatively 
longer time. As language development is the part of the human 
communication system, the weaker verbal communication function 
may hinder the cognitive development of children and be associated 
with relatively poor school academic achievements. 
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